DARWIN EU® – Frailty and polypharmacy among adults with selected cancers at the time of diagnosis

Study type

• Study type:
  Non-interventional study

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Medical condition to be studied:
  Breast cancer

  Ovarian cancer

  Endometrial cancer

  Prostate cancer

  Colorectal cancer

  Lymphoma
• Additional medical condition(s):
  Lung cancer, pancreatic cancer, leukemia and myeloma

Population studied

• Short description of the study population:
  The study population will include all individuals aged 18 years and above with a primary diagnosis of selected cancers (lung, breast, ovary, endometrium, prostate, pancreas, colorectal cancer, lymphoma, leukemia and myeloma) recorded between 01/01/2017 and 31/12/2022, with at least one year of prior history available before cancer diagnosis. Individuals with a diagnosis of cancer (any, excluding non-melanoma skin cancer) any time prior to the diagnosis of one of the selected cancers will be excluded. ; Additional eligibility of a minimum of 1 year of potential follow-up time prior to the end of last database observations will be imposed for the estimation of one-year hospitalisation and mortality rates if the data sources capture this information.
• Age groups:
  Adult and elderly population (≥18 years)

  Adults (18 to < 65 years)

  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Elderly (≥ 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)

Study design details

• Study design:
  A population-based cohort study of all incident cases of selected cancers will be conducted.
• Main study objective:
  The aim of this study is to estimate the prevalence of frailty and polypharmacy at the point of diagnosis of selected cancers in adults and to describe their characteristics.
• Setting:
  This study will be conducted using routinely collected health data from 6 databases in the DARWIN EU network of data partners from 6 European countries. All databases were previously mapped to the OMOP CDM.; Data sources ; 1. Clinical Practice Research Datalink (CPRD) GOLD, United Kingdom; 2. IQVIA Disease Analyzer Germany (IQVIA DA Germany), Germany ; 3. IQVIA Longitudinal Patient Database Belgium (IQVIA LPD Belgium), Belgium; 4. Integrated Primary Care Information Project (IPCI), The Netherlands; 5. Estonian Biobank (EBB), Estonia ; 6. Sistema d’Informació per al Desenvolupament de la Investigació en Atenció Primària (SIDIAP), Spain
• Data analysis plan:
  Population-level descriptive epidemiology:; - Prevalence rates of the condition of interest; Patient-level characterisation:; - Large-scale characterisation; - Patient-level characteristics; - Prognosis / progression to a pre-specified outcome

Documents

Study report

DARWIN EU_Report_P2-C1-009 Frailty and polypharmacy report_V4.pdf